BCR and acute lymphoblastic leukemia: Relevant to development of a therapeutic strategy, we have found that either canertinib or the clinically available ErbB inhibitor lapatinib combined with BCR/ABL inhibitors resulted increased cell death of ErbB2+Ph+ALL cells (Fig. 7).